Calton & Associates’s Dynavax Technologies DVAX Stock Holding History

Calton & Associates’s Portfolio DVAX Stock Details DVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,500	Closed	-$26K	–	572
2017 Q4	$26K	Buy	+1,500	New	+$30.1K	0.01%	836

Other funds holding DVAX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Calton & Associates's DVAX Position: Q1 2018 in Review

Calton & Associates sold out of Dynavax Technologies (DVAX) in Q1 2018, closing a stake of 1,500 shares — an estimated $26K sold.

Calton & Associates first reported a position in DVAX in Q4 2017 and held it in 1 quarter. The position peaked at $26K in Q4 2017. 139 funds tracked by Wall St. Rank hold DVAX as of Q1 2018.

Calton & Associates reported no remaining Dynavax Technologies position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 1,500 Dynavax Technologies shares in Q1 2018, an estimated $26K.
Calton & Associates first reported a position in Dynavax Technologies in Q4 2017 and held it in 1 quarter.
Calton & Associates's Dynavax Technologies position peaked at $26K in Q4 2017.
139 funds tracked by Wall St. Rank held Dynavax Technologies as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.